Category: Drugs and Pharmaceuticals
-
SET Enterprises launches 340b covered entity suspicious purchase identification service for pharmaceutical and biological manufacturers
PHOENIX, Ariz. — SET Enterprises, a leading independent management consulting firm serving the government pricing compliance needs of life sciences manufacturers, today announced the launch of SPI340B℠. This new service offering identifies specific 340B covered entities that exhibit suspicious purchasing patterns that suggest the entire volume of products purchased from pharmaceutical and biotechnology manufacturers may…
-
Divergent CRO Announces Launch of New Contract Research Organization
ATLANTA, Ga. — Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the…
-
Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group (PSG)
DALLAS, Texas — Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug benefit…
-
PSG Announces Release of Highly Anticipated ‘Trends in Specialty Drug Benefits Report’
DALLAS, Texas — Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research. PSG has been researching and reporting on drug benefit design for over 10…
-
NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group (PSG) Announces Artemetrx Extend – Revolutionary Drug Management Reporting Tool Offers Powerful User Insights
DALLAS, Texas — Artemetrx®, the industry’s most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.
-
Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference
AUSTIN, Texas — Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.
-
Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines
PFLUGERVILLE, Texas — Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo’s latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.
-
Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine
ROCHESTER, Minn. — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
-
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla. — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based…
-
Geminid Systems Unveils Pharmalite CRM to Boost Remote Engagement of Pharma Field Teams
REDWOOD CITY, Calif. — Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.